Abbott price target raised to $126 from $123 at Citi

Citi raised the firm’s price target on Abbott to $126 from $123 and keeps a Buy rating on the shares. The company’s Q4 results reflect the diversification of the business, a largely recovered Nutrition franchise, and a Medical Technology segment that is exceeding expectations, the analyst tells investors in a research note. The firm says there are few companies able to deliver this kind of revenue and earnings growth in the current environment.